Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
256 questions in 49 reviews · Haematology
current versionsNo studies 256 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Serious adverse events – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Complete response rate Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Escalated BEACOPP vs chemotherapy including ABVD Quality of life · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of days on which bleeding occurred ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR The amount of bleeding ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life score ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of days on which bleeding occurred ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR The amount of bleeding ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life score ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
GM‐CSF vs placebo Time to progression to AML · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
GM‐CSF vs placebo Quality of life · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs placebo Quality of life · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs placebo Severe adverse events · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of days on which bleeding occurred ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time from randomisation to first bleeding episode ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of platelet transfusions ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Thromboembolic events ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo or standard care Number of days on which bleeding occurred ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo or standard care Time from randomisation to first bleeding episode ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo or standard care Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Fatigue · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Anxiety · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of sleep · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion All‐cause mortality · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Respiratory deterioration attributable to transfusion‐associated circulatory overload (TACO), transfusion‐related acute lung injury (TRALI) or transfusion‐associated dyspnoea (TAD) · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Proportion of participants receiving plasma transfusions · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Line‐related complications · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Quality of life · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All cause mortality · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human soluble thrombomodulin vs heparin Resolution of respiratory failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human soluble thrombomodulin vs heparin Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |